PHARMACOLOGY-GUIDED RULE-BASED ADAPTIVE DOSE ESCALATION IN FIRST-IN-HUMAN STUDIES.

被引：0
|
作者：
van Hoogdalem, E. [1 ]
Van Lersel, T. [1 ]
Winter, E. [2 ]
Constant, J. [3 ]
机构：
[1] PRA Hlth Sci, Groningen, Netherlands
[2] PRA Hlth Sci, Blue, PA USA
[3] PRA Hlth Sci, Victoria, BC, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
OII-001
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [31] Pharmacology and Toxicology Studies Conducted for the First-in-Human Clinical Study of Neural Stem Cells in Parkinson's Disease
    Gonzalez, Rodolfo
    Garitaonandia, Ibon
    Abramihina, Tatiana
    Sherman, Glenn
    Noskov, Alexander
    Christiansen-Weber, Trudy
    Semechkin, Andrey
    Redmond, D. Eugene
    Snyder, Evan Y.
    Kern, Russell
    MOLECULAR THERAPY, 2017, 25 (05) : 140 - 140
  • [32] First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors
    Mahalingam, Devalingam
    Harb, Wael
    Patnaik, Amita
    Bullock, Andrea
    Watnick, Randolph S.
    Vincent, Melanie Y.
    Chen, Jian Jenny
    Wang, Suming
    Pestana, Harold
    Chao, Judy
    Mahoney, James
    Cieslewicz, Michael
    Watnick, Jing
    COMMUNICATIONS MEDICINE, 2024, 4 (01):
  • [33] DESIGNING OF PHASE I ONCOLOGY DOSE ESCALATION USING DOSE-EXPOSURE-TOXICITY MODEL AS A COMPLEMENTARY APPROACH TO RULE-BASED OR MODEL-BASED DOSE-TOXICITY MODELS.
    Pantoja, K.
    Lanke, S.
    Munafo, A.
    Victor, A.
    Habermehl, C.
    Schueler, A.
    Venkatakrishnan, K.
    Girard, P.
    Goteti, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S65 - S65
  • [34] First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors
    Devalingam Mahalingam
    Wael Harb
    Amita Patnaik
    Andrea Bullock
    Randolph S. Watnick
    Melanie Y. Vincent
    Jian Jenny Chen
    Suming Wang
    Harold Pestana
    Judy Chao
    James Mahoney
    Michael Cieslewicz
    Jing Watnick
    Communications Medicine, 4
  • [35] First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects
    Banfield, Christopher
    Rudin, Dan
    Bhattacharya, Indranil
    Goteti, Kosalaram
    Li, Gang
    Hassan-Zahraee, Mina
    Brown, Lisa S.
    Hung, Kenneth E.
    Pawlak, Sylvester
    Lepsy, Christopher
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (04) : 812 - 824
  • [36] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Mathiot, Laurent
    Combarel, David
    Cagnat, Justin
    Delahousse, Julia
    Ouali, Kaissa
    Marabelle, Aurelien
    Loriot, Yohann
    Ponce, Santiago
    Champiat, Stephane
    Broutin, Sophie
    Danlos, Francois-Xavier
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [37] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    ONCOLOGIST, 2019, 24 (04): : 455 - E121
  • [38] A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
    Carducci, Michael A.
    Wang, Ding
    Habermehl, Christina
    Bodding, Matthias
    Rohdich, Felix
    Lignet, Floriane
    Duecker, Klaus
    Karpenko, Oleksandr
    Pudelko, Linda
    Gimmi, Claude
    LoRusso, Patricia
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1638 - 1647
  • [39] First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors
    Eskens, F.
    Opdam, F.
    Gort, E.
    Gelderblom, H.
    Prestegarden, L.
    Pico-Navarro, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S758 - S758
  • [40] A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.
    Tolcher, Anthony W.
    Carneiro, Benedito A.
    Dowlati, Afshin
    Razak, Albiruni Ryan Abdul
    Chae, Young Kwang
    Villella, Jeannine A.
    Coppola, Sheryl
    Englert, Stefan
    Phillips, Andrew C.
    Souers, Andrew J.
    Salman, Zeena
    Penugonda, Sudhir
    Powderly, John D.
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345